Hitachi Vantara Introduces Data Reliability Engineering Services to Optimize Data Ecosystems
The latest offering through Hitachi Application Reliability Centers empowers data-driven leaders with trustworthy, secure and…
Year: 2023
Excision BioTherapeutics Appoints Former Pfizer Chairman and CEO Jeffrey B. Kindler to its Board of Directors
SAN FRANCISCO, June 01, 2023 (GLOBE NEWSWIRE) — Excision BioTherapeutics, Inc., a clinical-stage biotechnology company…
Excision BioTherapeutics Appoints Former Pfizer Chairman and CEO Jeffrey B. Kindler to its Board of Directors
SAN FRANCISCO, June 01, 2023 (GLOBE NEWSWIRE) — Excision BioTherapeutics, Inc., a clinical-stage biotechnology company…
Seer Launches the Proteograph XT Assay Kit: Allowing Labs to Easily Expand Their View of the Proteome and Scale Their Studies
Seer’s Proteograph XT pushes the boundaries of biological discovery by enabling rapid proteomics across a…
Seer Launches the Proteograph XT Assay Kit: Allowing Labs to Easily Expand Their View of the Proteome and Scale Their Studies
Seer’s Proteograph XT pushes the boundaries of biological discovery by enabling rapid proteomics across a…
Palisade Bio Promotes J.D. Finley to Chief Executive Officer
Carlsbad, CA, June 01, 2023 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”),…
Palisade Bio Promotes J.D. Finley to Chief Executive Officer
Carlsbad, CA, June 01, 2023 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”),…
Aleafia Health Announces Extension of Forbearance Under Loan Agreement With Senior Lender
TORONTO, June 01, 2023 (GLOBE NEWSWIRE) — Aleafia Health Inc. (TSX: AH, OTCQB: ALEAF) (“Aleafia…
Aleafia Health Announces Extension of Forbearance Under Loan Agreement With Senior Lender
TORONTO, June 01, 2023 (GLOBE NEWSWIRE) — Aleafia Health Inc. (TSX: AH, OTCQB: ALEAF) (“Aleafia…
Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients
– YUSIMRY™ (adalimumab-aqvh) will be the first biologic product offered by the Mark Cuban Cost Plus…
Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients
– YUSIMRY™ (adalimumab-aqvh) will be the first biologic product offered by the Mark Cuban Cost Plus…
Culture Biosciences Establishes Advisory Board of Biotech and Biopharma Executives to Guide the Corporate Strategy and Accelerate Growth
Seasoned sector leaders will advise Culture’s leadership in customer intelligence and innovation SAN FRANCISCO, June…
Culture Biosciences Establishes Advisory Board of Biotech and Biopharma Executives to Guide the Corporate Strategy and Accelerate Growth
Seasoned sector leaders will advise Culture’s leadership in customer intelligence and innovation SAN FRANCISCO, June…
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, June 01, 2023 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage…
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, June 01, 2023 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage…
IO Biotech Appoints Christine Richter, Ph.D., MBA, as Senior Vice President, Commercial and Program Lead
NEW YORK, June 01, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical…
IO Biotech Appoints Christine Richter, Ph.D., MBA, as Senior Vice President, Commercial and Program Lead
NEW YORK, June 01, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical…
Dyadic to Participate at Upcoming Events in June
JUPITER, Fla., June 01, 2023 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”)…
Dyadic to Participate at Upcoming Events in June
JUPITER, Fla., June 01, 2023 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”)…
Veru Announces Appointment of Dr. Erik Swenson and Dr. Robert Schooley to its Infectious Disease Scientific Advisory Board
MIAMI, FL, June 01, 2023 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a late clinical…